- Reuters•16 hours ago
The U.S. Food and Drug Administration approved Novartis AG's Rydapt as an initial treatment for acute myeloid leukemia (AML) as well as certain other blood disorders, the agency said on Friday. AML is a cancer that originates in the bone marrow and progresses rapidly, resulting in an abnormal increase in white blood cells. Rydapt is approved to be used along with chemotherapy to treat adults newly diagnosed with AML and carrying a specific genetic mutation called FLT3, the FDA said.
- Financial Times•17 hours ago
Biotech can easily get overshadowed by its larger and more profit-generating cousin, big pharma. However, the symbiosis between the two sectors has never been greater. Previously the small companies, usually ...
- Capital Cube•18 hours ago
Categories: Yahoo FinanceGet free summary analysis Novartis AG reports financial results for the quarter ended March 31, 2017. We analyze the earnings along side the following peers of Novartis AG – Johnson & Johnson, GlaxoSmithKline plc Sponsored ADR and Abbott Laboratories (JNJ-US, GSK-US and ABT-US) that have also reported for this period. Highlights Summary numbers: Revenues of ... Read more (Read more...)
NVS : Summary for Novartis AG Common Stock - Yahoo Finance
Novartis AG (NVS)
NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
|Day's Range||76.60 - 77.04|
|52 Week Range||66.93 - 83.58|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||27.51|
|Dividend & Yield||2.72 (3.71%)|
|1y Target Est||N/A|